For Q1 of the fiscal year ending May 2027, consolidated revenue was 11,894 million yen, down -8.6% year-over-year, operating income was 712 million yen, ordinary income was 808 million yen, and net income attributable to owners of parent was 700 million yen. The full-year forecast remains unchanged from the previous announcement: full-year revenue 54,000 million yen, operating income 4,000 million yen, and net income 3,000 million yen. The full-year dividend forecast is 45 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4577","jir_company_name":"Daito Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4577-20261014-01.pdf","jir_short_summary":"For Q1 of the fiscal year ending May 2027, consolidated revenue was 11,894 million yen, down -8.6% year-over-year, operating income was 712 million yen, ordinary income was 808 million yen, and net income attributable to owners of parent was 700 million yen. The full-year forecast remains unchanged from the previous announcement: full-year revenue 54,000 million yen, operating income 4,000 million yen, and net income 3,000 million yen. The full-year dividend forecast is 45 yen.","jir_summary":"### Performance Overview\nTotal revenue for the quarter was approximately 11.9 billion yen, down year-over-year, affected by higher raw material costs and inventory valuation losses. Operating income was 712 million yen, ordinary income was 808 million yen, and net income was 700 million yen, indicating a slowdown in profitability. However, the full-year plan remains unchanged from the previously announced figures, with expected revenue of 54,000 million yen, operating income of 4,000 million yen, and net income of 3,000 million yen.\n\n### Outlook and Investor Impact\nUnder the medium-term plan \"Daito Transformation Plan 2027,\" the company is promoting stable supply and production capacity enhancement in the pharmaceutical business. While attention is required regarding rising raw material costs and yen depreciation, supplemental explanatory materials for the financial results have been prepared to clarify future projections. Future performance will depend on recovery in revenue and improvements in cost management, which will determine the achievability of the full-year forecast.","jir_financial_highlights":"Revenue: 11,894 million yen (YoY -8.6%)\nOperating Income: 712 million yen (YoY -28.7%)\nOrdinary Income: 808 million yen (YoY -23.2%)\nNet Income Attributable to Owners of Parent: 700 million yen (YoY 0.6%)\nQuarterly Net Income per Share: yen 24.66 (\uff0d)\nEBITDA: 1,687 million yen (YoY Unknown)","jir_category":"","jir_hashtags":"#DaitoPharmaceutical, #FinancialResults, #MediumTermManagementPlan","jir_key_figures":"Revenue: 11,894 million yen (YoY -8.6%)\nOperating Income: 712 million yen (YoY -28.7%)\nNet Income Attributable to Owners of Parent: 700 million yen (YoY 0.6%)","jir_meta_title":"Daito Pharmaceutical Co., Ltd. Q1 Financial Summary for FY Ending May 2027 | Revenue 11,894 million yen, Full-Year Forecast Maintained","jir_meta_description":"Key points of Daito Pharmaceutical's Q1 FY ending May 2027 results: revenue 11,894 million yen (YoY -8.6%), operating income 712 million yen. Full-year forecast maintained at revenue 54,000 million yen, operating income 4,000 million yen, and net income 3,000 million yen. Supplemental explanatory materials available.","jir_og_title":"Daito Pharmaceutical Co., Ltd. Q1 Financial Summary for FY Ending May 2027 | Revenue 11,894 million yen","jir_og_description":"Daito Pharmaceutical's Q1 results: revenue 11,894 million yen and operating income 712 million yen. Full-year forecast is unchanged; monitor raw material cost trends and exchange rate impacts.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\",\\\"2027-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[11894,12050,12500,13000,54000],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\",\\\"2027-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[0,0,0,0,4000],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[11894],\\\"backgroundColor\\\":[\\\"#36a2eb\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gross Profit Margin\\\",\\\"Operating Margin\\\"],\\\"datasets\\\":[{\\\"data\\\":[21.46,5.98],\\\"backgroundColor\\\":\\\"#36a2eb\\\"}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":56861,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-130518","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n